Investment Analysts’ Recent Ratings Updates for Aardvark Therapeutics (AARD)

Aardvark Therapeutics (NASDAQ: AARD) has recently received a number of price target changes and ratings updates:

• 12/2/2025 – Aardvark Therapeutics is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $47.00 price target on the stock.
• 12/1/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/14/2025 – Aardvark Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/14/2025 – Aardvark Therapeutics had its price target lowered by analysts at Royal Bank Of Canada from $19.00 to $18.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Aardvark Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $26.00 price target on the stock.
• 10/8/2025 – Aardvark Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 10,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were bought at an average price of $9.66 per share, for a total transaction of $96,600.00. Following the completion of the acquisition, the chief executive officer owned 1,543,384 shares of the company’s stock, valued at approximately $14,909,089.44. This trade represents a 0.65% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Nelson Sun purchased 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was acquired at an average cost of $8.07 per share, with a total value of $48,420.00. Following the completion of the acquisition, the chief financial officer directly owned 105,484 shares of the company’s stock, valued at $851,255.88. The trade was a 6.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 36,000 shares of company stock valued at $305,630 over the last ninety days.

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.